In the base case analysis, pemetrexed-platinum chemotherapy treatment was associated with a mean cost of $12,983 and a mean quality-adjusted survival of 0.75 QALY in patients unselected by PD-L1 tumor expression. The gene discussed is CD274; the disease is neoplasm.